Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cahill

Showing results (281-290 of 425) with videos related to

Pageof 43
Sort By:
Human Vaccines & Immunotherapeutics|March 28, 2022
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of ageAnna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, et al.
Neuro-Oncology|July 7, 2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patientsKourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, et al.
Acta Neuropathologica Communications|January 7, 2021
Sporadic multiple meningiomas harbor distinct driver mutationsTareq A Juratli, Insa Prilop, Felix C Saalfeld, et al.
Journal of Neurosurgery|November 26, 2016
Targeted sequencing of SMO and AKT1 in anterior skull base meningiomasMatthew R Strickland, Corey M Gill, Naema Nayyar, et al.
Nature Communications|August 16, 2024
Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomasSyeda Maheen Batool, Ana K Escobedo, Tiffaney Hsia, et al.
Cancer Research|June 20, 2017
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion-Mediated CytotoxicityKensuke Tateishi, Fumi Higuchi, Julie J Miller, et al.
Journal of Neuro-Oncology|October 21, 2024
A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial designEthan A Wetzel, Amin I Nohman, Annie L Hsieh, et al.
Cancer|July 18, 2019
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutationsTareq A Juratli, Pamela S Jones, Nancy Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2015
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-HydroxyglutarateOvidiu C Andronesi, Franziska Loebel, Wolfgang Bogner, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 27, 2021
In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC-RX Array Coil for Whole-Brain MR Spectroscopic ImagingBijaya Thapa, Azma Mareyam, Jason Stockmann, et al.
Pageof 43

Showing results (281-290 of 425) with videos related to

Sort By:
Pageof 43
Human Vaccines & Immunotherapeutics|March 28, 2022
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of ageAnna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, et al.
Neuro-Oncology|July 7, 2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patientsKourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, et al.
Acta Neuropathologica Communications|January 7, 2021
Sporadic multiple meningiomas harbor distinct driver mutationsTareq A Juratli, Insa Prilop, Felix C Saalfeld, et al.
Journal of Neurosurgery|November 26, 2016
Targeted sequencing of SMO and AKT1 in anterior skull base meningiomasMatthew R Strickland, Corey M Gill, Naema Nayyar, et al.
Nature Communications|August 16, 2024
Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomasSyeda Maheen Batool, Ana K Escobedo, Tiffaney Hsia, et al.
Cancer Research|June 20, 2017
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion-Mediated CytotoxicityKensuke Tateishi, Fumi Higuchi, Julie J Miller, et al.
Journal of Neuro-Oncology|October 21, 2024
A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial designEthan A Wetzel, Amin I Nohman, Annie L Hsieh, et al.
Cancer|July 18, 2019
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutationsTareq A Juratli, Pamela S Jones, Nancy Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2015
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-HydroxyglutarateOvidiu C Andronesi, Franziska Loebel, Wolfgang Bogner, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 27, 2021
In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC-RX Array Coil for Whole-Brain MR Spectroscopic ImagingBijaya Thapa, Azma Mareyam, Jason Stockmann, et al.
Pageof 43